The Goldman Sachs Group Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price boosted by The Goldman Sachs Group from $28.00 to $32.00 in a report released on Wednesday,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on AGIO. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Truist Financial boosted their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Leerink Partners upped their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Friday, March 27th. Finally, JPMorgan Chase & Co. lifted their price objective on Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $41.44.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $34.19 on Wednesday. The company has a market cap of $2.00 billion, a P/E ratio of -4.81 and a beta of 0.78. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The business has a fifty day moving average of $28.61 and a two-hundred day moving average of $32.19.

Insider Activity

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,872 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $27.02, for a total transaction of $77,601.44. Following the completion of the transaction, the insider owned 34,793 shares in the company, valued at approximately $940,106.86. The trade was a 7.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Krishnan Viswanadhan sold 2,959 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares in the company, valued at $142,919.80. This trade represents a 36.53% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. lifted its stake in Agios Pharmaceuticals by 31.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 21,071 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 5,033 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Agios Pharmaceuticals during the fourth quarter worth $183,000. Seven Fleet Capital Management LP acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $864,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $25,000. Finally, Invesco Ltd. lifted its position in shares of Agios Pharmaceuticals by 12.3% in the fourth quarter. Invesco Ltd. now owns 142,580 shares of the biopharmaceutical company’s stock valued at $3,881,000 after acquiring an additional 15,604 shares in the last quarter.

Trending Headlines about Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: FDA engagement moves mitapivat toward accelerated approval in sickle cell disease — Agios completed a pre-sNDA meeting with the FDA, plans to submit an sNDA in the coming months and has already proposed the confirmatory trial required under accelerated approval. This materially improves the probability and timeline for a new indication and is the main catalyst behind the rally. Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval
• Positive Sentiment: Market reaction and analyst coverage reflect the FDA progress — multiple outlets report a sharp share-price jump (double-digit intraday gains) as investors price in a faster approval path for mitapivat. Elevated trading volume supports conviction behind the move. AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
• Positive Sentiment: Commercial progress in thalassemia — early uptake of Aqvesme shows physician interest (roughly one-third of patients identified as candidates), supporting Agios’s commercial execution beyond mitapivat. This diversification of revenue/relevance is supportive for medium‑term growth. PK Activation Gains Momentum in Thalassemia
• Neutral Sentiment: Insider selling noted — a recent small insider sale was reported; coverage frames it as contextual rather than signaling a material change to company prospects. Investors should compare size/frequency of insider transactions before reading into it. Insider Sells AGIO Shares Worth $82,000 — But Context Is Everything
• Negative Sentiment: Two law firms have opened investigations into Agios related to prior disclosures around the RISE UP mitapivat trial — potential securities‑litigation risk could pressure the stock if claims advance. This increases legal overhang and uncertainty despite the recent regulatory progress. Levi & Korsinsky Investigation Notice Gross Law Firm Investigation Notice
• Negative Sentiment: Goldman Sachs raised its price target to $32 but kept a “neutral” rating — the new PT is below the current market level, implying limited near‑term upside from this analyst and adding a cautious signal despite the FDA news. Goldman Sachs price target note
• Negative Sentiment: Technicals show short-term strain — a report notes AGIO passed below its 200‑day moving average recently, which may attract technical selling if it fails to hold momentum after the FDA news. Stock Passes Below 200 Day Moving Average

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.